淋巴瘤流行病学结局队列研究:设计、基线特征与早期结局
研究在美国8个学术中心前瞻性纳入7735例新诊断非霍奇金淋巴瘤(NHL)成人患者,构建多维度数据库;早期观察显示惰性B细胞和T细胞淋巴瘤总生存与SEER数据相似,侵袭性B细胞亚型较SEER高10%-15%。
要点
- LEO队列纳入7735例新诊断NHL患者,年龄≥18岁,来自美国8个学术中心。
- 中位诊断年龄62岁,覆盖49个州,包含黑人、西班牙裔、女性、年轻及农村居民。
- 侵袭性B细胞淋巴瘤(弥漫大B细胞和套细胞)1年和2年总生存较SEER高10%-15%。
核心结论
- LEO队列是研究临床、肿瘤、宿主遗传、流行病学及其他生物学因素在NHL预后和生存中作用的全国性资源。
研究设计与样本
- 前瞻性队列研究,2015年7月1日至2020年5月31日在美国8个学术中心纳入7735例新诊断NHL成人患者(年龄≥18岁)。
主要发现
- 诊断时中位年龄62岁(范围18-99岁),参与者来自49个美国州,包括538名黑人/非裔美国人、822名西班牙裔(不论种族)、3386名女性、716名年龄<40岁及1513名农村居民。
- 基线时采集血清/血浆(N=5883,76.0%)和胚系DNA(N=5465,70.7%),为四种主要NHL亚型构建组织芯片(N=1189),收集生活质量(N=5281,68.3%)和流行病学危险因素(N=4489,58.0%)数据。
- 截至2022年8月,共1492例死亡。
- 与基于人群的SEER数据(2015-2019)相比,LEO参与者的性别、黑人/非裔美国人、西班牙裔及NHL亚型分布相似,但亚洲人和80岁及以上患者比例较低。
- LEO观察到的1年和2年总生存率在惰性B细胞(滤泡和边缘区)及T细胞淋巴瘤中与SEER相似,但在侵袭性B细胞亚型(弥漫大B细胞和套细胞)中较SEER高10%-15%。
局限性
- 与SEER数据相比,LEO中亚洲人和80岁及以上患者比例较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To address the current and long-term unmet health needs of the growing population of non-Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18-99). Participants came from 49 US states and included 538 Black/African-Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age <40 years, and 1513 rural residents. At study baseline, we abstracted clinical, pathology, and treatment data; banked serum/plasma (N = 5883, 76.0%) and germline DNA (N = 5465, 70.7%); constructed tissue microarrays for four major NHL subtypes (N = 1189); and collected quality of life (N = 5281, 68.3%) and epidemiologic risk factor (N = 4489, 58.0%) data. Through August 2022, there were 1492 deaths. Compared to population-based SEER data (2015-2019), LEO participants had a similar distribution of gender, AA race, Hispanic ethnicity, and NHL subtype, while LEO was underrepresented for patients who were Asian and aged 80 years and above. Observed overall survival rates for LEO at 1 and 2 years were similar to population-based SEER rates for indolent B-cell (follicular and marginal zone) and T-cell lymphomas, but were 10%-15% higher than SEER rates for aggressive B-cell subtypes (diffuse large B-cell and mantle cell). The LEO cohort is a robust and comprehensive national resource to address the role of clinical, tumor, host genetic, epidemiologic, and other biologic factors in NHL prognosis and survivorship.
引用
- Cerhan JR, Maurer MJ, Link BK, et al. The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. Am J Hematol. 2024. PMID: 38217361. doi:10.1002/ajh.27202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。